<DOC>
	<DOCNO>NCT01597193</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics enzalutamide alone combination anastrozole , exemestane , fulvestrant patient incurable breast cancer .</brief_summary>
	<brief_title>Safety Study Enzalutamide ( MDV3100 ) Patients With Incurable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically confirm breast cancer accompany pathology report ; Submit unstained representative tumor specimen , either paraffin block ( prefer ) â‰¥ 10 unstained slide Received least 2 line systemic therapy advance setting ( enzalutamide alone arm ) ; Eastern Cooperative Oncology Group performance ( ECOG ) status 0 1 ; Estimated life expectancy least 3 month Severe concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate enrollment ; Pregnant lactating ; Known suspect brain metastasis leptomeningeal disease ; History another malignancy within previous 5 year curatively treat situ carcinoma ; For patient enrolled receive enzalutamide plus anastrozole exemestane fulvestrant must receive tamoxifen medication know potent CYP3A4 inducer inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>enzalutamide</keyword>
	<keyword>MDV3100</keyword>
	<keyword>breast cancer</keyword>
</DOC>